Inflammation, Microbiota, and Prostate Cancer.

[1]  I. Thompson,et al.  Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial , 2016, The Prostate.

[2]  G. Parmigiani,et al.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.

[3]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[4]  R. Vessella,et al.  A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells , 2015, Cancer Immunology Research.

[5]  A. D. De Marzo,et al.  Bacterial Prostatitis Enhances 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP)–Induced Cancer at Multiple Sites , 2015, Cancer Prevention Research.

[6]  Hassan Razvi,et al.  The microbiome of the urinary tract—a role beyond infection , 2015, Nature Reviews Urology.

[7]  D. Waugh,et al.  Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells , 2014, Oncotarget.

[8]  Jennifer R. Rider,et al.  Genetic variation across C‐reactive protein and risk of prostate cancer , 2014, The Prostate.

[9]  Young-Hwa Goo,et al.  Novel Lipid Droplet–Associated Serine Hydrolase Regulates Macrophage Cholesterol Mobilization , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[10]  R. Vandenbroucke,et al.  Pro-inflammatory effects of matrix metalloproteinase 7 in acute inflammation , 2013, Mucosal Immunology.

[11]  A. D. De Marzo,et al.  The role of inflammation in prostate cancer. , 2014, Advances in experimental medicine and biology.

[12]  Ali Amin Al Olama,et al.  The genetic epidemiology of prostate cancer and its clinical implications , 2014, Nature Reviews Urology.

[13]  N. Maitland,et al.  JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. , 2013, Cancer research.

[14]  A. D. De Marzo,et al.  A mouse model of chronic prostatic inflammation using a human prostate cancer‐derived isolate of Propionibacterium acnes , 2013, The Prostate.

[15]  Martin J. Aryee,et al.  DNA Methylation Alterations Exhibit Intraindividual Stability and Interindividual Heterogeneity in Prostate Cancer Metastases , 2013, Science Translational Medicine.

[16]  Stacey A. Kenfield,et al.  A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer , 2012, Clinical Cancer Research.

[17]  E. Porcellini,et al.  Genetic factors regulating inflammation and DNA methylation associated with prostate cancer , 2012, Prostate Cancer and Prostatic Diseases.

[18]  J. Mefford,et al.  Association of the Innate Immunity and Inflammation Pathway with Advanced Prostate Cancer Risk , 2012, PloS one.

[19]  H. Klocker,et al.  Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. , 2012, The American journal of pathology.

[20]  D. English,et al.  Interleukin‐6 promoter variants, prostate cancer risk, and survival , 2012, The Prostate.

[21]  J. Kere,et al.  Centrosomal Localization of the Psoriasis Candidate Gene Product, CCHCR1, Supports a Role in Cytoskeletal Organization , 2012, PloS one.

[22]  D. Tomar,et al.  Nucleo-Cytoplasmic Trafficking of TRIM8, a Novel Oncogene, Is Involved in Positive Regulation of TNF Induced NF-κB Pathway , 2012, PloS one.

[23]  Z. Culig,et al.  Interleukin-6: A multifunctional targetable cytokine in human prostate cancer , 2012, Molecular and Cellular Endocrinology.

[24]  R. Kittles,et al.  Fine-Mapping of IL16 Gene and Prostate Cancer Risk in African Americans , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[25]  Shanru Li,et al.  Foxp4 Is Dispensable for T Cell Development, but Required for Robust Recall Responses , 2012, PloS one.

[26]  Cabral A. Bigman-Galimore,et al.  Variation in IL10 and Other Genes Involved in the Immune Response and in Oxidation and Prostate Cancer Recurrence , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[27]  P. Kraft,et al.  Genetic variation in the toll‐like receptor 4 and prostate cancer incidence and mortality , 2012, The Prostate.

[28]  A. D. De Marzo,et al.  Prostate cancer and inflammation: the evidence , 2012, Histopathology.

[29]  S. Baylin,et al.  Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. , 2011, Cancer cell.

[30]  K. Pantel,et al.  The anti‐interleukin‐6 antibody siltuximab down‐regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study , 2011, The Prostate.

[31]  A. D. De Marzo,et al.  Transcription-Induced DNA Double Strand Breaks: Both Oncogenic Force and Potential Therapeutic Target? , 2011, Clinical Cancer Research.

[32]  D. Shoskes,et al.  The etiology and management of acute prostatitis , 2011, Nature Reviews Urology.

[33]  Elaine A. Ostrander,et al.  Genetic Polymorphisms in Inflammation Pathway Genes and Prostate Cancer Risk , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[34]  G. Weinstock,et al.  Characteristic Male Urine Microbiomes Associate with Asymptomatic Sexually Transmitted Infection , 2010, PloS one.

[35]  M. Loda,et al.  Genetic variation in RNASEL associated with prostate cancer risk and progression. , 2010, Carcinogenesis.

[36]  P. Nelson,et al.  American Journal of Epidemiology Original Contribution Use of Aspirin and Other Nonsteroidal Antiinflammatory Medications in Relation to Prostate Cancer Risk Caucasian and African-american Men 35–74 Years of Age Residing in King County, Washington, Who Were Diagnosed , 2022 .

[37]  Martin J. Aryee,et al.  Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements , 2010, Nature Genetics.

[38]  O. Kaminuma,et al.  Selective Down-Regulation of Th2 Cytokines by C-Terminal Binding Protein 2 in Human T Cells , 2010, International Archives of Allergy and Immunology.

[39]  J. Pinski,et al.  Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer , 2010, Clinical Cancer Research.

[40]  M. Thun,et al.  PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). , 2010, Carcinogenesis.

[41]  Z. Culig,et al.  Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells , 2010, Endocrine-related cancer.

[42]  A. Bergh,et al.  Morphological transition of proliferative inflammatory atrophy to high‐grade intraepithelial neoplasia and cancer in human prostate , 2009, The Prostate.

[43]  E. Platz,et al.  Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. , 2009, Current opinion in pharmacology.

[44]  Hui-Yi Lin,et al.  Cytokine genetic polymorphisms and prostate cancer aggressiveness. , 2009, Carcinogenesis.

[45]  A. D. De Marzo,et al.  Epigenetic alterations in human prostate cancers. , 2009, Endocrinology.

[46]  W. Isaacs,et al.  Association of IL10 and Other immune response‐ and obesity‐related genes with prostate cancer in CLUE II , 2009, The Prostate.

[47]  Brice A P Wilson,et al.  Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer , 2009, Proceedings of the National Academy of Sciences.

[48]  Dietmar Fuchs,et al.  Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. , 2008, Endocrine-related cancer.

[49]  Zhijin Wu,et al.  DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. , 2008, Cancer research.

[50]  Jun Luo,et al.  Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis , 2008, Modern Pathology.

[51]  S. Baylin,et al.  Double Strand Breaks Can Initiate Gene Silencing and SIRT1-Dependent Onset of DNA Methylation in an Exogenous Promoter CpG Island , 2008, PLoS genetics.

[52]  P. Johnston,et al.  Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. , 2008, Carcinogenesis.

[53]  Hui-Yi Lin,et al.  Interactions of cytokine gene polymorphisms in prostate cancer risk. , 2007, Carcinogenesis.

[54]  D. Albanes,et al.  Association of IL-10 polymorphisms with prostate cancer risk and grade of disease , 2008, Cancer Causes & Control.

[55]  S. Araki,et al.  Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. , 2007, Cancer research.

[56]  A. Gao,et al.  Interleukin‐6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression , 2007, The Prostate.

[57]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[58]  U. Langsenlehner,et al.  Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study. , 2007, European journal of cancer.

[59]  A. D. De Marzo,et al.  The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. , 2007, Cancer research.

[60]  Y. Song,et al.  NF‐κB as a potential molecular target for cancer therapy , 2007 .

[61]  R. Cardiff,et al.  Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model. , 2006, Neoplasia.

[62]  S. Cole,et al.  Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. , 2006, The Journal of urology.

[63]  R. Hayes,et al.  Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. , 2006, Cancer research.

[64]  Yi Lu,et al.  Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. , 2006, Cancer research.

[65]  Christopher M. Wilson,et al.  Prostatitis and serum prostate-specific antigen , 2005, Current urology reports.

[66]  J. Pinski,et al.  Interleukin‐6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation , 2004, International journal of cancer.

[67]  J. Hicks,et al.  Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. , 2003, The American journal of pathology.

[68]  D. Fuchs,et al.  Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. , 2003, The American journal of pathology.

[69]  D. Tindall,et al.  p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. , 2002, Cancer research.

[70]  Nicholas Bruchovsky,et al.  Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.

[71]  J. Carpten,et al.  Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk , 2002, Nature Genetics.

[72]  B. Ames,et al.  Are vitamin and mineral deficiencies a major cancer risk? , 2002, Nature Reviews Cancer.

[73]  R. Eeles,et al.  Influence of cytokine gene polymorphisms on the development of prostate cancer. , 2002, Cancer research.

[74]  Naftali Kaminski,et al.  Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[75]  K. Klinger,et al.  Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 , 2002, Nature Genetics.

[76]  E. Keller,et al.  Anti‐interleukin‐6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice , 2001, The Prostate.

[77]  A. De Marzo,et al.  Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. , 2000, Urology.

[78]  P. Maxwell,et al.  Bcl‐2 proto‐oncogene expression in low‐ and high‐grade prostatic intraepithelial neoplasia , 2000, BJU international.

[79]  R. Hayes,et al.  Sexual behaviour, STDs and risks for prostate cancer , 2000, British Journal of Cancer.

[80]  H. Klocker,et al.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.

[81]  J. Brooks,et al.  CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[82]  J. Eastham,et al.  Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. , 1998, Journal of the National Cancer Institute.

[83]  M. Lazarus,et al.  An investigation of polymorphism in the interleukin-10 gene promoter. , 1997, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[84]  A. J. Garrett,et al.  CANCER XENOGRAFTS IN NUDE MICE , 1976, The Lancet.

[85]  F W MULSOW,et al.  Cancer incidence and mortality , 2019, Health at a Glance: Europe.